Bryleos is developing BRY101, a metabolic modulator that increases intracellular NAD levels to target mitochondrial dysfunction, neuroinflammation, and oxidative stress associated with neurodegenerative and neuromuscular disorders. This multi-pathway approach diverges from traditional single-target drug development, aiming to improve patient outcomes in complex neurological conditions.